Journals / Hacettepe Journal of Biology and Chemistry / 2020 / Cilt: 48 - Sayı: 1

Synthesis of Two 7, 8-Dioxabicyclo[4.1.1]Octan-3-Yl)- Steroid Derivatives and Evaluation of Their Inotropic Activity in an Animal Model

İki 7, 8-Dioksabisiklo [4.1.1] Oktan-3-Yl) - Steroid Türevlerinin Sentezi ve Hayvan Modelinde İnotropik Aktivitelerinin Değerlendirilmesi

Pages
1–12
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Theresults showed that compound 3 increased LVP in a dose-dependent manner and this effect was inhibited by nifedipine.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this study was synthesizing two 7,8-dioxabicyclo[4.1.1]octan-3-yl)-steroid derivatives (compounds 3 or 4) to evaluate their inotropic activity in vitro.
📊
Key Findings & Data:The first stage was achieved by the preparation of two 7,8-dioxabicyclo[4.1.1]octan-3-yl)-steroid derivatives using some chemical strategies.
💡
Conclusion & Impact:Theresults showed that compound 3 increased LVP in a dose-dependent manner and this effect was inhibited by nifedipine.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The aim of this study was synthesizing two 7,8-dioxabicyclo[4.1.1]octan-3-yl)-steroid derivatives (compounds 3 or 4) to evaluate their inotropic activity in vitro. The first stage was achieved by the preparation of two 7,8-dioxabicyclo[4.1.1]octan-3-yl)-steroid derivatives using some chemical strategies. Then, the inotropic activity of both steroid derivatives against left ventricularpressure (LVP) was evaluated in an isolated rat heart model using Bay-k-8644, nifedipine, aucubin and L-NAME as controls. Theresults showed that compound 3 increased LVP in a dose-dependent manner and this effect was inhibited by nifedipine. Otherresults showed that compound 4 decreased LVP in a dose-dependent manner and this effect was blocked in presence of L-NAME.All these data indicate that 1) the positive inotropic activity exerted by compound 3 was through type L calcium channel activation; 2) the negative inotropic effect of 4 was via nitric oxide synthase activation; these phenomena could be due to the differentfunctional groups involved in the chemical structure of compounds 3 and 4. Therefore, the inotropic activity that exerts thesecompounds could be translated as good candidates for the treatment of heart failure.

Özet

Bu çalışmanın amacı, inotropik aktivitelerini in vitro olarak değerlendirmek için iki adet 7,8-dioksabisiklo [4.1.1] oktan-3-il) -steroid türevini (bileşik 3 veya 4) sentezlemekti. İlk aşama, bazı kimyasal stratejiler kullanılarak iki 7,8-dioksabisiklo [4.1.1] oktan3-il) -steroid türevinin hazırlanmasıyla başarıldı. Daha sonra, her iki steroid türevinin sol ventrikül basıncına (LVP) karşı inotropik aktivitesi, kontrol olarak Bay-k-8644, nifedipin, aucubin ve L-NAME kullanılarak izole edilmiş bir sıçan kalp modelinde değerlendirildi. Sonuçlar, bileşik 3’ün LVP’yi doza bağlı bir şekilde arttırdığını ve bu etkinin nifedipin tarafından inhibe edildiğini gösterdi. Diğer sonuçlar, bileşik 4’ün LVP’yi doza bağlı bir şekilde azalttığını ve bu etkinin L-NAME varlığında bloke edildiğini gösterdi. Tüm bu veriler, 1) Bileşik 3 tarafından uygulanan pozitif inotropik aktivitenin, L tipi kalsiyum kanalı aktivasyonu yoluyla olduğunu; 2) 4’ün negatif inotropik etkisi, nitrik oksit sentaz aktivasyonu ile olmuştur. Bu fenomen, bileşik 3 ve 4’ün kimyasal yapısına dahil olan farklı fonksiyonel gruplar nedeniyle olabilir.

🔖

Cite This Article

VALDERDE, L. F., NEXTICAPA, M. R., ESPINO, E. A. G., ARMAND, V. M., RAMOS, M. L., BALLOTE, Y. B., CEDILLO, F. D. (2022). Synthesis of Two 7, 8-Dioxabicyclo[4.1.1]Octan-3-Yl)- Steroid Derivatives and Evaluation of Their Inotropic Activity in an Animal Model. Hacettepe Journal of Biology and Chemistry, Cilt: 48 - Sayı: 1, 1–12. https://ajindex.com/articles/528971

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. K.K. Ho, J.L. Pinsky, W.B. Kannel, D. Levy, The epidemiology of heart failure: the Framingham Study, J. Am. Coll. Cardiol., 22 (1993) A6-A13
  2. J.J. McMurray, S. Adamopoulos, S.D. Anker, A. Auricchio, M. Böhm, M. Gomez, ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC, Eur. J. Heart. Fail., 14 (2012) 803-869
  3. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Wittes, The effect of spironolactone on morbidity and mortality in patients with severe heart failure, N. Eng. J. Med., 341 (1999) 709-717
  4. Digitalis Investigation Group, The effect of digoxin on mortality and morbidity in patients with heart failure, N. Eng. J. Med., 336 (1999) 525-533
  5. M.A. Pfeffer, J.J. McMurray, E.J. Velazquez, J.L. Rouleau, L. Køber, A.P. Maggioni, J.D. Leimberger, Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both, N. Eng. J. Med., 349 (2003) 1893-1906
  6. J.N. Cohn, G. Tognoni, A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure, N. Eng. J. Med., 345 (2001) 1667-1675
  7. A. Mebazaa, M.S. Nieminen, M. Packer, A. Cohen-Solal, Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial, J. Am. Med. Assoc., 297 (2007) 1883-1891
  8. M. Kivikko, S. Antila, J. Eha, L. Lehtonen, P. Pentikäinen, Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure, J. Clin. Pharmacol., 2 (2002) 43-51
  9. D. Baim, A. McDowell, J. Cherniles, E. Monrad, A. Parker, J. Edelson, W. Grossman, Evaluation of a new bipyridine inotropic agent-milrinone in patients with severe congestive heart failure, N. Engl. J. Med., 309 (1983) 748-756 10. M.R. Rose, E. Glassma, F.C. Spencer, Arrhythmias following cardiac surgery: relation to serum digoxin levels, Am. Heart J., 89 (1975) 288-294
  10. K. Silberbauer, B. Stanek, H. Templ, Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition, Br. J. Clin. Pharmacol., 14 (1982) 87S-93S 12. D.J. Greenblatt, J. Koch-Weser, Adverse reactions to spironolactone: a report from the Boston Collaborative Drug Surveillance Progr